St Jude Medical study shows benefits of EnligHTN system

St Jude Medical has announced data from a recent study that supports the safety and efficacy of the EnligHTN renal denervation system.

Results from the trial showed that the technology offers a safe, effective and sustained reduction in office and ambulatory blood pressure measurements at six months, with no serious acute device or therapy-specific adverse events reported.

EnligHTN is a multi-electrode ablation system that uses a catheter to deliver radiofrequency energy to create lesions along the renal sympathetic nerves, thus causing systolic and diastolic blood pressure to decrease.

It was granted European CE Mark approval and launched commercially earlier this year, while it is yet to be released in the US.

Frank Callaghan, president of St Jude Medical's cardiovascular and ablation technologies division, said: "We are pleased with the rapid and sustained reduction of blood pressure to date and remain committed to advancing the science, technology and clinical evidence surrounding this important new procedure."

This comes after the firm reported clinical trial data last week showing how its Amplatzer PFO Occluder system can help prevent recurrent cryptogenic stroke.